Pycnogenol
Lymphedema
National Center for Complementary and Integrative Health (NCCIH)Phase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Lymphedema cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TACROLIMUS Odense University Hospital | Phase 2/3 | B |
Lymfactin® Herantis Pharma Plc. | Phase 2 | B |
Sodium Selenite University Health Network, Toronto | Phase 2 | B |
Pentoxifylline M.D. Anderson Cancer Center | Phase 2 | B |
PRAVASTATIN M.D. Anderson Cancer Center | Phase 2 | CCC |
View all 17 →
Same molecule, other indications
Pycnogenol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →